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Abstract: Background and objectives: Exercise can help ease withdrawal symptoms of smokers.
However, there is little information about the physiological responses, such as cardiorespiratory and
lactate (La) responses, during exercise from light to moderate intensity combined with transdermal
nicotine patches (TNPs) in smokers. This study aimed to investigate the effect of TNPs on the
cardiorespiratory and La responses during exercise at light to moderate intensity. Materials and
Methods: Fourteen young men (8 non-smokers, 6 current smokers) aged 20 to 26 years participated in
this study. They performed an incremental graded submaximal exercise test using an electromagnetic
cycle ergometer set from 30 to 210 W with (TNP condition) or without a TNP (control condition)
in a random order. The TNP was applied to the left arm 8–10 h prior to starting the exercise to
achieve the peak level of blood nicotine concentration. Heart rate (HR), rate of perceived exertion
(RPE), oxygen consumption (VO2), ventilation (VE), and blood La at rest and during exercise were
measured and analyzed. Results: The HR at rest was significantly higher in the TNP condition than
in the control condition (TNP; 74.7 ± 13.8 bpm, control; 65.3 ± 10.8 bpm, p < 0.001). There was no
interaction (condition × exercise intensity) between any of the variables, and VO2, VE, RPE, and
La during exercise were not significantly different between the conditions. However, HR during
exercise was 6.7 bpm higher on average in the TNP condition. Conclusions: The HR during exercise
was greater at light to moderate intensity with a TNP. Our study results will guide clinicians or health
professionals when prescribing exercise programs combined with TNPs for healthy young smokers.
Keywords: smoking habits; smoking cessation; cardiovascular disease; mortality; weight gain;
exercise prescription; exercise program; heart rate; clinical setting
1. Introduction
Smoking is a major cause of cancer, cardiovascular diseases, diabetes, and many other diseases;
however, smoking cessation reduces the risk of developing these major chronic diseases and extends
life expectancy [1–3]. The World Health Organization has set a goal of reducing the global smoking
Medicina 2019, 55, 348; doi:10.3390/medicina55070348 www.mdpi.com/journal/medicina
Medicina 2019, 55, 348 2 of 10
rate by 30% by 2025 [4]. The provision of a smoking cessation program for smokers is essential for
public health [5].
However, smoking cessation is not necessarily easy for smokers owing to different factors. First,
nicotine withdrawal symptoms, such as cravings, anxiety and irritability, depression, and smoking
urges, appear in the early stages of smoking cessation [6]. For this reason, the majority of smokers who
attempt to quit smoking relapsed. To solve this problem and reduce nicotine withdrawal symptoms,
nicotine replacement therapy (NRT), such as the transdermal nicotine patches (TNPs) and nicotine
gum, in addition to counseling are the most common methods for smokers in the clinical setting. In
particular, TNPs are easy to use and provide a slow, steady level of nicotine over a long period as
compared to nicotine gum [7]. Furthermore, TNPs can be applied safely in normal individuals [8,9]
and various populations (e.g., patients with cardiac disease, pregnant women) [10,11] using low or
high nicotine doses.
Physical activity and exercise have been proposed as an aid for smoking cessation [12], and
performing physical activity and exercise may have the potential to lessen some of the negative
consequences of smoking withdrawal [13,14]. For example, acute bouts of exercise (e.g., walking,
cycle ergometer) have been found to have a positive effect in the reduction of nicotine withdrawal
symptoms and smoking craving [15–17], which are important factors that could lead to smoking
relapse. In addition, a combination of exercise and NRT is effective for smoking cessation [18]. Thus, it
is recommended to perform physical activity and exercise during smoking cessation to attenuate the
nicotine withdrawal symptoms and smoking craving.
However, nicotine affects the human physiological responses, such as cardiovascular responses. For
example, heart rate (HR) is controlled by the sympathetic and parasympathetic nervous systems, and the
parasympathetic nervous system predominates as compared to the sympathetic nervous system at the
resting state [19,20], although nicotine stimulates the central, sympathetic, and parasympathetic nervous
systems as well as the secretion of catecholamine (adrenaline and noradrenaline) [21]. As a result, TNPs
increase the HR by 6–10 bpm [22,23]. In addition, previous studies investigating the physiological
responses during physical activity and exercise combined with nicotine products reported that HR
during exercise was higher in nicotine conditions than in controls [24–26]. In contrast, Mundel et al.
using TNPs reported that there were no significant differences in cardiorespiratory responses (HR,
ventilation (VE), and oxygen consumption (VO2)) between TNP and control experiments. However,
they investigated the cardiorespiratory responses during exercise with TNPs at only one exercise
intensity until exhaustion (77% maximum VO2), and no study has been conducted to investigate the
effect of TNPs on the cardiorespiratory responses during exercise at lower intensities. As mentioned
previously, nicotine stimulates the sympathetic nervous systems and the secretion of catecholamine;
thus, we hypothesize that TNPs increase cardiorespiratory responses during lower exercise intensity
as compared to exercises without TNPs. In addition, exercise intensity should be dependent on age,
fitness level, and health condition, and it is common to perform exercises at light to moderate intensity,
such as walking and cycle ergometer exercise, at the beginning of the exercise program in a clinical
setting. Therefore, a further study is needed to examine cardiorespiratory responses during exercise at
light to moderate intensity for smoking cessation combined with TNPs.
The purpose of this study was to investigate the effect of TNPs on the cardiorespiratory and lactate
(La) responses during exercise at light to moderate intensity.
2. Materials and Methods
2.1. Participants
This study included 14 adult male individuals (8 non-smokers, 6 current smokers) aged 20 to
26 years (age, 23.3 ± 2.3 years; height, 174.3 ± 5.6 cm; weight, 67.6 ± 10.6 kg; body mass index (BMI),
22.2 ± 2.5 kg/m2). They were recruited from our university through printed advertisements and by
word of mouth. Participants underwent an annual health examination at their university and were
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found to have normal blood pressure (BP) and electrocardiograms and had no history of established
cardiovascular disease, pulmonary disease, or neurological disease. We excluded participants taking
medicines or supplements. Table 1 shows the participant characteristics and anthropometric data. All
participants had regular exercise habits (1–3 days per week). Prior to the study, all included individuals
provided written consent to participate after receiving information about the procedures and purpose
of the study. The study protocol was approved by the Research Ethics Review Board of the Juntendo
University Graduate School of Health and Sports Science (approval no. 27–24).
The sample size was calculated with GPower 3.1.3 (Dusseldorf, Germany) based on an assumption
of the clinically significant differences in HR responses between TNPs and without TNPs apriori as
effect size d = 0.9 of two dependent means (matched pairs), with α error prob = 0.05 and power (1–β)
= 0.8. The required total sample size was estimated to be n = 13.
Table 1. Participants’ characteristics (mean ± SD, 95% confidence interval).
Variables Age(years)
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
Smokers, n = 6 21.7 ± 1.4 *(20.2, 23.1)
177.8 ± 4.6 *
(172.7, 182.3)
72.3 ± 15.7
(56.0, 88.8)
22.7 ± 4.0
(18.5, 26.9)
Non-smokers, n = 8 24.2 ± 2.3(22.6, 25.8)
172.2 ± 5.2
(168.7, 176.0)
64.8 ± 5.4
(61.0, 68.7)
21.8 ± 1.1
(21.0, 22.6)
Total, n = 14 23.3 ± 2.3(22.0, 24.5)
174.3 ± 5.6
(171.4, 177.1)
67.6 ± 10.6
(62.0, 73.3)
22.2 ± 2.5
(20.8, 23.5)
Note: SD, standard deviation; BMI, body mass index; *Significantly different vs. non-smokers, p < 0.05.
2.2. Experimental Design
The study was a random crossover single-blind design (with or without TNP conditions on two
separate days). In session 1, the participants performed either the TNP or control sessions. In session 2,
they performed either the TNP or control sessions, all the participants completed both the experiments
on two separate days within one week. To eliminate the influence of execution order, the allocation
of the TNP or control to sessions 1 and 2 was randomized among participants. The participants in
this study refrained from doing any strenuous physical activity, including general exercise, from the
day prior to the start of the experiment, and they started fasting (no water restriction) four hours
before starting the experiment. Height and body weight were measured before the exercise. For
each participant, the resting oxygen consumption (VO2) was measured in both sessions using an
indirect calorimeter (AE-300s, Minato Medical Science Co., Ltd., Osaka, Japan) while sitting on a cycle
ergometer and maintaining a resting position for 5 min with a face mask attached. After measuring the
resting VO2, each participant performed session 1 or 2. All the measurements were carried out in a
laboratory, where the temperature and humidity of the internal atmosphere were adjusted to 20 ◦C
and 50%, respectively.
2.3. Transdermal Nicotine Patch (TNP)
The present study used TNPs (Novartis, 10 cm2, 17.5 mg nicotine patch, release rate 7 mg nicotine
per 24 h). A TNP was applied to the left arm at 21:00 to 22:00 to ensure that the blood nicotine
concentration reached the maximum value during exercise, because previous studies have reported
that the blood nicotine concentration reached the maximum level at 8–10 h after TNP application [7,27].
In the control condition, a seal with similar size but without nicotine was attached to the left arm at
21:00 to 22:00. Furthermore, we attached another seal onto the TNPs and the control seals so as to blind
the participants to the experimental protocol. Given that TNPs may cause headache and nausea and
those could affect the study results, all participants underwent TNP application with a lower nicotine
content for 10 h prior to the experiment, as a pre-screening method; only those who did not experience
adverse effects, such as headaches and nausea, were included.
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2.4. Incremental Graded Exercise Test and Indirect Calorimetry Measurement
All participants performed an incremental graded submaximal exercise test using an
electromagnetic cycle ergometer (PowerMax Vll, COMBI WELNESS. Tokyo, Japan). The graded
exercise test consisted of eight incremental stages, starting at 0.5 kp for 4 min, and then increasing to
0.5 kp (30 W) every 4 min until 3.5 kp (210 W). Participants were asked to maintain the cadence at
60 rpm and to adjust the rhythm with the sound of a metronome during the exercise test. Respiratory
gas measurement using indirect calorimetry (AE-300s, Minato Medical Science Company, Ltd.) and a
face mask was carried out in our laboratory as previously described [28]. All data were processed
every 30 s, and the VO2 and carbon dioxide production (VCO2) were measured. The last 2 min in each
stage was used to evaluate the VO2 and VCO2.
2.5. Heart Rate, Ratings of Perceived Exertion, and Blood Lactate Concentration
HR was recorded during the whole experiment using an electrocardiogram device (Fukuda
Electronics Co., Ltd. Tokyo, Japan). Three beats were recorded 15 s before the end of each stage; the
average value was taken as the HR of each stage. The rate of perceived exertion (RPE) was recorded
using the 6–20-step Borg scale [29] after each stage. Blood samples (20 µL) were collected from the
earlobe using a capillary tube [30] using a Biosen S-Line device (EKF Diagnostik, Barleban, Germany)
before the exercise and immediately after each stage in both experiments. The La threshold (LT) is the
initial breakpoint in the elevation of blood La concentrations. The determination of LT was based on
visual inspection by five trained staff members, and the mean LT was calculated from three of the five
results [31].
2.6. Statistical Analysis
Microsoft Office Excel 2017 and PASW Statistics version 20.0 (SPSS, IBM Inc. BM Corp., Armonk,
NY, USA) were used for data processing and statistical analyses, respectively. All the variable results are
presented as mean ± standard deviation. To examine the main effect (Condition and Exercise intensity)
and interaction (condition × exercise intensity), two-way repeated analysis of variance (ANOVA) was
conducted for each variable. One-way repeated ANOVA was conducted to examine the main effect for
each variable in each condition separately if a significant interaction was observed. A paired t-test
was conducted to determine the significant differences between TNP and control experiments. The
statistical significance level was set at 0.05.
3. Results
All participants successfully completed both experimental sessions.
Figure 1 shows the physiological responses at rest and during the exercise test in both experimental
sessions. HR at rest was significantly higher in the TNP condition than in the control condition (TNP;
74.7 ± 13.8 bpm, control; 65.3 ± 10.8, p < 0.001). Other variables at rest, VO2, VE, and La, were not
significantly different between the two conditions.
During the exercise test, two-way repeated ANOVA shows no interaction (condition × exercise
intensity) for all variables, and VO2, VE, La, and RPE during exercise were not significantly different
between the TNP and control conditions. However, HR was significantly higher in the TNP condition
than in the control condition (p < 0.001), HR during exercise was 6.7 bpm higher on average in the
TNP condition than in the control condition. LT was not significantly different (TNP; 117.8 ± 18.6 W,
control; 116.6 ± 17.2 W, p = 0.518) between the two conditions.
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Figure 1. Physiological responses at rest and during exercise (Ex) for the transdermal nicotine patch 
(TNP) and control conditions. (a) heart rate (HR), (b) oxygen consumption (VO2), (c) ventilation (VE), 
(d) rate of perceived exertion (RPE) and (e) lactate (La). The symbol “white circle” is the control 
condition, and the symbol “black circle” is the TNP condition. Two-way repeated analysis of variance 
(ANOVA) shows no significant interaction between condition and exercise intensity, and heart rate 
(HR) during exercise is significantly higher in the TNP condition than in the control condition (p < 
0.001). *p < 0.05, significant difference between conditions. 
Figure 1. Physiological responses at rest and during exercise (Ex) for the transdermal nicotine patch
(TNP) and control conditions. (a) heart rate (HR), (b) oxygen consumption (VO2), (c) ventilation (VE),
(d) rate of perceived exertion (RPE) and (e) lactate (La). The sy bol “white circle” is the control
condition, and the symbol “black circle” is the TNP condition. Two-way repeated analysis of variance
(ANOVA) shows no significant interaction between condition and exercise intensity, and heart rate (HR)
during exercise is significantly higher in the TNP condition than in the control condition (p < 0.001).
* p < 0.05, significant difference between conditions.
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4. Discussion
It has been reported that exercise suppresses nicotine withdrawal symptoms and smoking cessation
at the same time as NRT, and now combining NRT and exercise is expected to play an important role
in quitting smoking [18]. However, the physiological responses, such as cardiorespiratory and La
responses, during exercise when using TNPs have not been extensively studied. It is important to
investigate these physiological responses because nicotine increases resting HR and BP. In this study,
we investigated these responses during submaximal exercise at light to moderate intensity with or
without TNPs. The main finding of the study is that TNPs increased HR by 9–10 bpm at rest and during
exercise (6.7 bpm higher on average in the TNP condition). However, the relationship between exercise
intensity and HR responses during exercise was not significantly different between both conditions,
and TNP did not increase the HR throughout the incremental exercise. In addition, there were no
significant differences in VO2, VE, RPE, and La concentration.
The parasympathetic nervous system predominates and controls the HR at the resting state [19,20].
However, nicotine increases HR owing to different factors, such as stimulation of the central nervous
system, vasodilation, and stimulation of catecholamine release (adrenalin, noradrenalin) [32]. TNPs
also increase HR at rest by 6–10 bpm [22,23]. We previously used higher doses of TNP (Novartis,
20 cm2, 35 mg nicotine patch, release rate 14 mg nicotine per 24 h) and reported that the mean HR at
rest was significantly higher in the TNP condition than in the control condition (TNP: 63.7 ± 8.2 bpm,
control: 56.9 ± 7.3 bpm; p = 0.011) [33]. Similarly, HR at rest for the TNP condition in the present
study was significantly higher than that for the control condition (TNP; 74.7 ± 13.8 bpm, control;
65.3 ± 10.8 bpm, p < 0.001), which is consistent with the findings of previous studies. Furthermore,
two-way repeated ANOVA shows no interaction (condition × exercise intensity) in HR responses
during exercise between both conditions. However, the HR during exercise was significantly higher in
the TNP condition than in the control condition (Figure 1). Furthermore, we examined the relationship
between HR and exercise intensity-adjusted covariances with HR at rest, the slope of regression was
not significant in both conditions, with the intercept being higher in the nicotine condition (data
now shown). This result indicated that TNP did increase HR at baseline, although the relationship
between exercise intensity and HR in the TNP condition was almost similar to that in the control
condition. Previous studies investigating the effects of nicotine during exercise have reported that
nicotine gum and spray, which acutely elevate blood nicotine levels compared to TNPs, increase HR
during exercise [24–26]. In contrast, a previous study using TNPs during exercise reported that there
were no significant differences between TNP and control conditions [34]. Although the administration
methods of nicotine are different among gum, spray, and patch applications, the exercise intensity
during exercise is suggested as the reason for the differences in HR during exercise. In our study and
that of Perkins et al., participants performed exercise at very light to moderate intensity, whereas the
participants of Mundel et al.’s study started exercise at a high intensity (77% VO2 max) until exhaustion.
In general, sympathetic nervous activity and catecholamine levels increase with increasing exercise
intensity [20,35]; therefore, the high-intensity exercise and greater sympathetic nervous system activity
may have masked the effects of nicotine.
With regard to VO2, VE, and RPE, there were no significant differences between both experiments,
which is in accordance with the findings of Mundel et al.’s study [34]. The RPE is a widely used
psycho-physical tool to assess subjective perception of effort during exercise [36] and to monitor the
intensity of exercise, because it is related to physiological markers of the stress response to exercise [37].
Furthermore, a strong relationship exists between RPE and HR during exercise in general [29]. However,
Perkins et al. reported that RPE during exercise at low intensity did not differ between the nicotine
spray intake and control conditions [25]. Moreover, in studies using different nicotine concentrations
(low to high), HR increased in a nicotine dose-dependent manner (the greater the volume of nicotine, the
greater the increase in HR), but it was reported that RPE was not related to nicotine dose [24]. Similarly,
there were no significant differences in RPE between our study and Mundel et al.’s study using TNPs.
Given that the participants in previous studies, including our study, were healthy young adults, there
Medicina 2019, 55, 348 7 of 10
would be no significant differences in RPE. Although the relationship between nicotine and RPE is
unclear in the present study, it is thought that the nicotine products, including TNPs and nicotine spray,
do not increase negative bodily sensations, fatigue, and perceived exertion. Further studies are needed
to examine the perceived exertion and RPE during exercise with TNPs for other populations.
Our hypothesis was that the La responses during exercise with a TNP and no TNP differ,
because nicotine stimulates the sympathetic and parasympathetic nervous systems and secretion of
catecholamine (adrenaline and noradrenaline). Previous studies have reported that the catecholamine
concentrations during incremental exercise have been shown to start to increase steeply with increasing
work intensity, which is similar to the LT [38,39]. However, there were no interactions (condition ×
exercise intensity) of the main effects of nicotine during exercise between the TNP and control conditions;
LT did not differ significantly between both conditions (TNP; 117.8 ± 18.6 W, control; 116.6 ± 17.2 W,
p = 0.518). As mentioned previously, we applied the TNPs the night before the experiment to achieve
the peak nicotine level, and higher HR at rest and during exercise (Figure 1a) is expected when the
blood nicotine level is at its peak. However, our results indicate that La concentration at rest and
during exercise was not influenced by TNPs.
Smoking cessation reduces the risk of major chronic diseases and extends life expectancy [1–3].
In contrast, the relationship between stopping smoking and body weight has been known for many
years, with the majority of smokers who attempted to quit smoking gaining body weight, in addition
to the nicotine withdrawal symptoms [40,41]. From this background, increasing energy expenditure
by exercise per se and/or combined exercise and NRT has received much interest in smokers who
desire to stop smoking in the clinical setting. Thus, the implications for exercise prescription during
smoking cessation should be discussed here. In the general principles of exercise prescription, exercise
intensity is one of the most important areas, as well as frequency, exercise time, and exercise type; direct
measurements of HR and VO2 are recommended for individualized exercise prescription for greater
accuracy, but when these are not feasible, estimation of exercise intensity is acceptable [37]. In general,
HR monitoring using an electrocardiogram (ECG) monitor or automated HR monitor during exercise
and exercise prescription based on HR and RPE have become an established and common method in
the clinical setting. However, assuming exercise prescriptions at the time of smoking cessation using
TNPs, given that TNPs increases HR at rest, the HR reserve (HRR) methods may be preferable for
exercise prescription as compared to the %HRmax method. If the exercise program used the %HR
method despite the same value of RPE, exercise intensity could be underestimated as compared to the
HRR method. As an alternative method of setting the exercise intensity, a method measuring LT is
useful. Performing at LT is safe and favorable on aerobic capacity and metabolic syndrome and related
disorders, such as hypertension and glucose intolerance [42–44].
However, our study has several limitations. First, all the study participants were healthy young
men. The smoking history of the participants in this study was shorter by several years than those of
previous studies, but the cardiorespiratory responses during exercise with TNP in other populations
might be different from those in our younger participants. For example, Fletcher and Peto [45] reported
that the reduction in forced expiratory volume in one second (FEV1) for smokers became apparent
after 40 years of age, as compared to that of non-smokers. Moreover, previous studies have shown
that women metabolize nicotine more rapidly than men [46,47]. It is unclear whether our findings on
the influence of smoking history and sex on exercise tolerance can be applied to other populations.
Second, we did not measure the BP level at rest and during exercise, and further studies are still needed.
Previous studies reported that nicotine increases both HR and BP levels in smokers [22,23], and we
speculated that the BP level was also higher in the TNP condition in our young men. Furthermore, the
double product (HR × systolic BP), which is considered to be a useful index of myocardial oxygen
uptake [38] during exercise would be higher in the TNP condition. Third, we used a lower dose
of TNPs in this study, although generally smokers may try a higher dose of TNPs at the beginning
of smoking cessation. Therefore, the cardiorespiratory responses, particularly HR, will increase in
higher doses of TNPs. Fourth, the present study used aerobic-type exercises. Recently, it was found
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that anaerobic-type exercises, such as resistance exercises, also have the potential to reduce nicotine
withdrawal symptoms [48,49]. The exercise type and energy profile of these exercises are different than
in aerobic-type exercises at light to moderate intensity, whereas resistance exercise using machines
or free-weights at high intensity acutely increases HR and blood pressure up to 140–160 bpm (80%
HRmax) [50,51]. Therefore, physiological responses during exercise combined with TNPs could differ
between aerobic-type exercises and anaerobic-type exercises, and a further study is needed to examine
cardiorespiratory responses during other types of exercises. Last, the present study is a random
crossover single-blind design. Because double-blind design is more reliable than single-blind, further
studies with a double-blind design are needed to examine the effect of TNPs.
5. Conclusions
When comparing the cardiorespiratory responses and La concentration during exercise at light to
moderate intensity between TNP and control conditions, the HR during exercise was 6.7 bpm higher
on average in the TNP condition than in the control condition. However, there were no significant
differences in VO2, VE, RPE, and La between both conditions. For practical recommendations for
exercise prescription during smoking cessation in the clinical setting, clinicians should consider that
TNPs increase the HR at rest and during exercise when prescribing exercise intensity and monitoring
physiological responses, and the HRR methods may be preferred when prescribing the exercise
intensity based on HR. The results of our study are valuable for clinicians and health professionals to
guide them when prescribing exercise programs combined with TNPs during smoking cessation in the
clinical setting, such as cardiology and respiratory medicine, for healthy young individuals.
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